Home » Improper Procedures Lead To 483 for PET Drugmaker
Improper Procedures Lead To 483 for PET Drugmaker
The FDA chided positron emission tomography (PET) drug manufacturer IBA Molecular North America for not properly handling complaints and quality production.
Drug GMP Report
Drugs GMPs Inspections and Audits QualityDrug GMP Report
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May